Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.624 DKK -2.4% Market Closed
Market Cap: 697.8m DKK
Have any thoughts about
Bioporto A/S?
Write Note

Bioporto A/S
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioporto A/S
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Bioporto A/S
CSE:BIOPOR
Other Current Assets
kr2.3m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Other Current Assets
€36.7m
CAGR 3-Years
19%
CAGR 5-Years
30%
CAGR 10-Years
81%
B
Bavarian Nordic A/S
CSE:BAVA
Other Current Assets
kr59m
CAGR 3-Years
21%
CAGR 5-Years
10%
CAGR 10-Years
13%
F
Fluoguide AS
STO:FLUO
Other Current Assets
kr180k
CAGR 3-Years
0%
CAGR 5-Years
61%
CAGR 10-Years
N/A
No Stocks Found

Bioporto A/S
Glance View

Market Cap
697.8m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.257 DKK
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Bioporto A/S's Other Current Assets?
Other Current Assets
2.3m DKK

Based on the financial report for Jun 30, 2024, Bioporto A/S's Other Current Assets amounts to 2.3m DKK.

What is Bioporto A/S's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
25%

Over the last year, the Other Current Assets growth was -63%. The average annual Other Current Assets growth rates for Bioporto A/S have been 25% over the past three years .

Back to Top